CD70

CD70 (Cluster of Differentiation 70) is a protein that in humans is encoded by CD70 gene.[1] CD70 is a ligand for CD27.

CD70 molecule
Identifiers
SymbolCD70
Alt. symbolsCD27LG, TNFSF7
NCBI gene970
HGNC11937
OMIM602840
RefSeqNM_001252
UniProtP32970
Other data
LocusChr. 19 p13

Clinical significance

The CD70 protein is expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes have low CD70 expression.[2]

Drug development

ARGX-110 is a CD70-specific antibody that is currently under investigation for the treatment of hematological malignancies. It is being developed by the Belgian company arGEN-X. In December 2013 a first part of a phase 1b trial was completed. In January 2014 a safety and efficacy phase of the study started.[3]

Vorsetuzumab mafodotin is a CD70-targeted antibody-drug conjugate that started clinical trials for renal cell carcinoma.[4]

gollark: Real men fill their entire computer with mineral oil.
gollark: My desktop-repurposed-as-mostly-unused-server just uses the stock cooler, though I was looking at switching it to passive.
gollark: Not necessarily.
gollark: Well, it's more expensive.
gollark: Water cooling doesn't automatically make it good.

See also

References
  1. "NCBI".
  2. Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC (2005). "Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas". Mol. Cancer Ther. 4 (12): 2037–44. doi:10.1158/1535-7163.MCT-05-0253. PMID 16373719.
  3. "ARGX-110: first-in-class CD70-targeting antibody with unique mode of therapeutic action". arGEN-X. Archived from the original on 9 March 2015. Retrieved 28 February 2015.
  4. Seattle Genetics Third Quarter 2013 Financial Report


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.